Try it
OBG · Complications of pregnancy: immune thrombocytopenia
Sample itemA woman at 14 weeks, known since adolescence to have an isolated low platelet count of about 60,000 per microlitre, has no bleeding and a normal blood pressure. Her peripheral smear is otherwise normal. What is the best management?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
A. Observation, steroids or IVIG if counts fall
Immune thrombocytopenia that pre-dates pregnancy is managed by monitoring. Treatment with prednisolone or IVIG is started if the platelet count falls below about 30,000, or if bleeding occurs or delivery approaches. Platelets are transfused only for bleeding or before surgery. Maternal IgG antibodies cross the placenta and may cause neonatal thrombocytopenia.
Option by option
A. Observation, steroids or IVIG if counts fall (correct)
Correct. Asymptomatic stable counts are observed, and steroids or IVIG are used if they fall or bleeding occurs.
B. Splenectomy during the second trimester of pregnancy
Splenectomy is reserved for refractory cases and not offered routinely in pregnancy.
C. Termination of the pregnancy on medical grounds
The condition is not an indication for termination.
D. Immediate prophylactic transfusion of platelet concentrates
Prophylactic platelet transfusion is ineffective in the long term because antibodies destroy the platelets.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More OBG questions
- Antenatal careA woman's last menstrual period began on 10 January 2026. Using Naegele's rule, what is…
- Obstetric drugsCarboprost (15-methyl PGF2α) is contraindicated in which condition?
- Hypertensive disorders of pregnancyA primigravida at 34 weeks has a blood pressure of 150/100 mmHg on two occasions and 2+…
- Obstetric immunologyAn Rh-negative mother delivers an Rh-positive baby. When should anti-D immunoglobulin be…